Table 6.
Clinical outcomes following bevacizumab discontinuation
| Variable | Timing of discontinuationa) |
p-value | |
|---|---|---|---|
| LD | ED | ||
| Overall population | |||
| Discontinuation to progression (wk) | 62 | 27 | |
| Median (95% CI) | - | 11.4 (8.0-14.9) | - |
| Range | - | 2.3-132.1 | |
| Non-enhancing progression, n (%)b) | 13 (21.3) | 3 (13.6) | 0.746 |
| Progression to death (wk)b) | |||
| Median (95% CI) | 14.4 (12.5-16.4) | 15.7 (12.3-19.1) | 0.251 |
| Discontinuation to death (wk) | |||
| Median (95% CI) | - | 28.6 (25.0-32.1) | - |
| GBM | |||
| Discontinuation to progression (wk) | 38 | 17 | |
| Median (95% CI) | - | 13.1 (9.3-17.0) | - |
| Range | - | 2.4-132.1 | |
| Non-enhancing progression, n (%)c) | 6 (15.8) | 1 (7.1) | 0.655 |
| Progression to death (wk)c) | |||
| Median (95% CI) | 14.0 (10.9-17.1) | 15.6 (14.3-16.9) | 0.219 |
| Discontinuation to death (wk) | |||
| Median (95% CI) | - | 28.7 (23.0-34.4) | - |
| AG | |||
| Discontinuation to progression (wk) | 23 | 10 | |
| Median (95% CI) | - | 6.0 (1.6-10.4) | - |
| Range | - | 2.3-19.4 | |
| Non-enhancing progression, n (%)d) | 7 (30.4) | 2 (25.0) | > 0.99 |
| Progression to death (wk)d) | |||
| Median (95% CI) | 14.6 (11.7-17.5) | 19.9 (3.3-36.4) | 0.919 |
| Discontinuation to death (wk) | |||
| Median (95% CI) | - | 27.9 (20.7-35.0) | - |
LD, late discontinuation; ED, early discontinuation; CI, confidence interval; GBM, glioblastoma multiforme; AG, anaplastic glioma.
a)
The patients shown in this table were categorized into LD and ED groups as determined at the time of the last follow-up visit,
b)
Calculated for 83 patients who progressed on bevacizumab (61 in LD and 22 in ED groups, respectively),
c)
Calculated for 52 patients who progressed on bevacizumab (38 in LD and 14 in ED groups, respectively),
d)
Calculated for 31 patients who progressed on bevacizumab (23 in LD and 8 in ED groups, respectively).